Table 2.
Characteristics | All Patients (n = 30) |
---|---|
Sex, female | 12 (40%) |
Age at initial diagnosis, median (years) | 49 (26–71) |
Comorbidities | |
Diabetes | n = 3 (27%) |
Arterial hypertension | n = 3 (27%) |
Primary tumor localization | |
Pancreas | n = 14 (47%) |
Ileum | n = 2 (6%) |
Stomach | n = 7 (23%) |
Other: | n = 7 (23%) |
Rectum | n= 2 |
Thymus | n = 1 |
Lung | n = 1 |
Larynx | n = 1 |
Cortex of suprarenal gland | n = 1 |
CUP | n = 1 |
Median survival (months), range | n = 123 (0–176) |
No. of patients alive | n = 11 (37%) |
No. of death patients | n = 7 (23%) |
No. of patients lost-to-follow-up | n = 12 (40%) |
Metastases | n = 20 |
Hepatic metastases | n = 20 (20/24; 83%) |
Lymph node metastases | n = 16 (16/25; 64%) |
Bone metastases | n = 6 (6/22; 27%) |
Peritoneal carcinomatosis | n = 7 (7/22; 32%) |
Grading: | n = 29 |
G1 | n = 0 |
G2 | n = 2 (7%) |
G3 | n = 25 (93%) |
Ki-67 (%), median (range) | 28 (20–95) |
Ki-67 ≤ 20 | n = 8 (36%) |
Ki-67 >20 | n = 14 (64%) |
T stage | n = 9 |
T1 | n = 0 |
T2 | n = 2 (22%) |
T3 | n= 3 (33%) |
T4 | n = 4 (44%) |
Relapse | |
no | n = 19 (95%) |
yes | n = 1 (5%) |
Functional disease | |
no | n = 16 (80%) |
yes | n = 4 (20%) |
SSR expression | n = 22 |
no | n = 16 (73%) |
yes | n = 6 (27%) |
Creatinine (mg/dL), median; (range) | 0.85; (0.52–1.60) |
Creatine < 1 | n = 21 (81%) |
Creatine ≥ 1 | n = 5 (19%) |
Chromogranin A (μg/L), median; (range) | 138 (1–454) |
<137 μg/L | n = 4 (50%) |
≥137 μg/L | n = 4 (50%) |
NEC, neuroendocrine carcinomas; CUP, cancer of unknown primary; SSR, somatostatin receptor.